Inhibrx Biosciences Inc.
NASDAQ: INBX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mark Lappe
- Employees
- 109
- Headquarters
- La Jolla, United States
- IPO year
- 2024
- Market cap
- $1.4B
- Website
- https://www.inhibrx.com
Loading INBX…
Loading profile data…Frequently asked questions about INBX
What does Inhibrx Biosciences Inc. (INBX) do?
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the preci...
Where does INBX trade?
Inhibrx Biosciences Inc. (INBX) trades on the NASDAQ.
What sector is INBX in?
Inhibrx Biosciences Inc. (INBX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Inhibrx Biosciences Inc.?
Mark Lappe is the chief executive officer of Inhibrx Biosciences Inc. (INBX).
Where is Inhibrx Biosciences Inc. headquartered?
Inhibrx Biosciences Inc. is headquartered in United States.
Does INBX pay a dividend?
Yes — Inhibrx Biosciences Inc. (INBX) paid a trailing twelve-month dividend of USD 0.85 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did INBX go public?
Inhibrx Biosciences Inc. (INBX) completed its initial public offering in 2024.